CLINICAL AI

OpenEvidence, the dominant medical search and AI platform serving nearly half of all US physicians, has acquired Amaro, a Google Ventures-backed artificial intelligence advertising company, in a strategic move to strengthen its advertising infrastructure while maintaining free access for healthcare professionals. The acquisition brings together two AI-native companies with complementary technologies, positioning OpenEvidence to scale its ad-supported business model more effectively.
Founded by brothers Kush Khosla and Sauren Khosla, Amaro specialized in helping companies analyze and optimize end-to-end advertising deployment using intelligent automation. The startup, which was backed by both Google Ventures and Greycroft, developed fast, AI-driven advertising solutions that align perfectly with OpenEvidence's need for sophisticated advertising infrastructure to support its free-to-physician platform.
"OpenEvidence powers over half a million clinical conversations per day to verified American clinicians—for free," explained Zachary Ziegler, co-founder of OpenEvidence. The company's mission centers on ensuring every patient receives care from physicians with access to the highest quality medical information, regardless of practice resources. This acquisition provides the technological foundation to scale this vision sustainably through an ad-supported model that doesn't burden healthcare providers with subscription fees.
The strategic rationale becomes clear when considering OpenEvidence's remarkable growth trajectory and market position. The platform currently serves more than 40% of physicians in the United States, who log in daily to make high-stakes clinical decisions at the point of care. With 90,000 new clinicians joining monthly and active use across over 10,000 hospitals and medical centers, OpenEvidence has achieved unprecedented adoption rates in healthcare technology.
This acquisition follows OpenEvidence's recent $210 million Series B funding round, which valued the company at $3.5 billion. The funding round, co-led by Google Ventures and Kleiner Perkins, demonstrated significant investor confidence in the company's approach to AI-powered clinical decision support. Sangeen Zeb, general partner at Google Ventures who backed both companies, noted the natural fit: "The Khosla brothers have built an exceptional team at Amaro—combining resilience, vision, and technical excellence. This acquisition is a great fit, as Amaro's team and technology will help OpenEvidence accelerate its growth."
The acquisition reflects broader trends in healthcare AI, where sustainable business models are crucial for long-term success and widespread adoption. By strengthening its advertising infrastructure through Amaro's expertise, OpenEvidence can continue providing free access to evidence-based medical information while building a financially robust platform. This approach ensures that resource-constrained practices maintain equal access to cutting-edge clinical decision support tools, potentially reducing healthcare disparities and improving patient outcomes across diverse practice settings.